You are here

tofersen

Will Biogen’s Qalsody Be a Catalyst for Gene-Specific ALS Research?

Will Biogen’s Qalsody Be a Catalyst for Gene-Specific ALS Research?

BioSpace

drug development

Flag link:

FDA approves Biogen and Ionis’ Tofersen for rare genetic form of ALS

FDA approves Biogen and Ionis’ Tofersen for rare genetic form of ALS

Medical Marketing and Media

Ionis Pharmaceuticals

Flag link:

5 FDA decisions to watch in the second quarter

5 FDA decisions to watch in the second quarter

BioPharma Dive

Sarepta Therapeutics

Duchenne Muscular Dystrophy

Seres Therapeutics

Flag link:

Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement

Ionis Rockets As Biogen-Partnered ALS Drug Wins Key Endorsement

Investors Business Daily

Ionis Pharmaceuticals

Flag link:

FDA advisers support conditional clearance of Biogen’s ALS drug

FDA advisers support conditional clearance of Biogen’s ALS drug

BioPharma Dive

Flag link:

Neurofilament as a surrogate endpoint goes on trial in tofersen adcomm

Neurofilament as a surrogate endpoint goes on trial in tofersen adcomm

BioSpace

Ionis Pharmaceuticals

clinical trials

Flag link:

Biogen/ Ionis ALS therapy set for March FDA AdCom meeting

Biogen/ Ionis ALS therapy set for March FDA AdCom meeting

Seeking Alpha

Ionis Pharmaceuticals

Flag link:

Biogen's ALS Drug Tofersen Filing Accepted in Europe

Biogen's ALS Drug Tofersen Filing Accepted in Europe

Zacks.com

Flag link:

Biogen's Q3 revenue declines 10% as focus shifts to new Alzheimer's and ALS drug candidates

Biogen's Q3 revenue declines 10% as focus shifts to new Alzheimer's and ALS drug candidates

Endpoints

Alzheimer's disease

Flag link:

Biogen's ALS ambitions on pause as FDA delays approval decision by 3 months

Biogen's ALS ambitions on pause as FDA delays approval decision by 3 months

Fierce Biotech

Flag link:

Biogen bolsters case for ALS drug under FDA review with new published data

Biogen bolsters case for ALS drug under FDA review with new published data

MedCity News

Flag link:

FDA, in another test of its flexibility, agrees to review Biogen’s closely watched ALS drug

FDA, in another test of its flexibility, agrees to review Biogen’s closely watched ALS drug

BioPharma Dive

Flag link:

ANA 2021 – Ionis rocked by tofersen flop

ANA 2021 – Ionis rocked by tofersen flop

EP Vantage

Ionis Pharmaceuticals

clinical trials

Flag link:

Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS

Biogen Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Extension in SOD1-ALS

Yahoo Finance

clinical trials

Flag link:

Promised EAP Date Approaching for Biogen's Highly Publicized ALS Drug

Promised EAP Date Approaching for Biogen's Highly Publicized ALS Drug

BioSpace

Flag link:

Following pressure, Biogen to start compassionate use program for ALS drug tofersen

Following pressure, Biogen to start compassionate use program for ALS drug tofersen

Seeking Alpha

compassionate use guidelines

Flag link:

Biogen Shares Positive Data on Phase I/II Trial of Tofersen for SOD1-ALS

Biogen Shares Positive Data on Phase I/II Trial of Tofersen for SOD1-ALS

BioSpace

clinical trials

Flag link:

Biogen’s Experimental Drug Shows Promise for Genetic Form of ALS

Biogen’s Experimental Drug Shows Promise for Genetic Form of ALS

BioSpace

Ionis Pharmaceuticals

Flag link: